Dyne Therapeutics (NASDAQ:DYN) CFO Erick Lucera Sells 2,362 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) CFO Erick Lucera sold 2,362 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $20.37, for a total value of $48,113.94. Following the transaction, the chief financial officer owned 121,563 shares of the company’s stock, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Erick Lucera also recently made the following trade(s):

• On Wednesday, May 13th, Erick Lucera sold 1,448 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.36, for a total transaction of $26,585.28.

Dyne Therapeutics Stock Up 1.6%

Shares of DYN stock opened at $20.94 on Friday. The firm’s fifty day moving average price is $18.45 and its two-hundred day moving average price is $18.11. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00. The firm has a market capitalization of $3.46 billion, a P/E ratio of -6.50 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the firm posted ($1.05) earnings per share. On average, equities analysts predict that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of analyst reports. Sanford C. Bernstein upped their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th. Morgan Stanley dropped their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Chardan Capital reiterated a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently added to or reduced their stakes in DYN. JPMorgan Chase & Co. grew its stake in Dyne Therapeutics by 9.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock valued at $42,570,000 after buying an additional 278,466 shares during the last quarter. Aberdeen Group plc increased its position in Dyne Therapeutics by 99.0% during the fourth quarter. Aberdeen Group plc now owns 1,108,145 shares of the company’s stock worth $21,675,000 after acquiring an additional 551,412 shares during the period. Vanguard Group Inc. grew its position in shares of Dyne Therapeutics by 27.6% during the 3rd quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock worth $123,469,000 after purchasing an additional 2,109,257 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at approximately $5,191,000. Finally, Fisher Asset Management LLC bought a new position in Dyne Therapeutics during the 4th quarter worth $4,891,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.